Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Elutia Inc. is a commercial-stage regenerative medicine company focused on developing and marketing biological scaffolds derived from extracellular matrix (ECM) for soft tissue repair and reconstruction. The company operates in wound care and surgical reconstruction markets with products like CanGaroo envelope for cardiac device infections and Revita for soft tissue reinforcement. With a $100M market cap, negative cash flow of approximately $25M annually, and a distressed balance sheet (0.44 current ratio), the company faces significant liquidity challenges while attempting to commercialize its product portfolio.
Elutia sells proprietary biological scaffolds through direct sales force and distribution partners to hospitals and surgical centers. Products are priced at premium levels ($2,000-$8,000 per unit for CanGaroo) based on clinical differentiation in reducing infection rates and improving surgical outcomes. The company's ECM technology platform provides some competitive moat through manufacturing expertise and clinical data, but faces competition from synthetic mesh products and other biologics. Gross margins of 44% reflect manufacturing complexity and small scale, while massive operating losses (-146% operating margin) indicate the company is burning cash to fund commercial expansion and R&D without achieving breakeven scale.
CanGaroo adoption rates and hospital formulary wins, particularly at high-volume cardiac centers
Clinical trial results and publications demonstrating infection reduction or cost-effectiveness versus standard of care
Liquidity events including equity raises, debt financing, or strategic partnerships that extend cash runway beyond 12-18 months
FDA regulatory decisions on new product approvals or expanded indications for existing products
Quarterly revenue growth rates and gross margin trends indicating commercial traction
Reimbursement pressure from CMS and private payers questioning cost-effectiveness of premium biologics versus lower-cost synthetic alternatives, particularly as healthcare systems focus on value-based care
Regulatory pathway uncertainty for combination products and evolving FDA standards for biological scaffolds requiring additional clinical evidence
Technology disruption from synthetic mesh innovations, antimicrobial coatings, or alternative infection prevention strategies that could commoditize the market
Well-capitalized competitors including Integra LifeSciences, Medtronic, and BD offering competing biological and synthetic products with larger sales forces and established hospital relationships
Physician adoption barriers due to learning curve with new products and loyalty to existing solutions, particularly in conservative cardiac surgery market
Pricing pressure from group purchasing organizations and hospital value analysis committees demanding outcomes data to justify premium pricing
Imminent liquidity crisis with current ratio of 0.44 and estimated cash runway of 6-12 months requiring dilutive equity raise or debt restructuring in 2026
Negative tangible book value and negative equity position limiting financing options and making bankruptcy or asset sale scenarios plausible if commercial traction disappoints
Debt/equity ratio of -0.60 suggests complex capital structure potentially including convertible notes or warrants that could create additional dilution
moderate - Elective surgical procedures (hernia repair, plastic surgery) are somewhat discretionary and decline during recessions as patients delay non-urgent procedures and hospitals reduce inventory. However, cardiac device implantations are less cyclical as they address life-threatening conditions. Hospital capital budgets for new product adoption tighten during economic downturns, extending sales cycles. The company's small revenue base makes it vulnerable to even modest procedure volume declines.
High interest rates significantly impact Elutia through multiple channels: (1) Higher cost of capital makes equity financing more dilutive and debt financing more expensive or unavailable for cash-burning biotechs, (2) Rising rates compress valuation multiples for unprofitable growth companies as investors demand higher returns, (3) Hospital systems face higher borrowing costs which can reduce willingness to adopt premium-priced new products. With negative cash flow and likely need for near-term financing, the company is highly sensitive to credit market conditions.
Critical - With a 0.44 current ratio and estimated $25M annual cash burn, Elutia faces acute refinancing risk. The company likely needs to access capital markets in 2026 to avoid liquidity crisis. Tightening credit conditions or risk-off sentiment in biotech could make financing unavailable or prohibitively dilutive. High yield credit spreads directly impact the company's ability to secure debt financing as an alternative to equity raises.
momentum/speculative - The 72% three-month return followed by -58% one-year return indicates highly speculative trading driven by clinical catalysts, financing announcements, or short squeezes rather than fundamental value. Institutional ownership is likely minimal given the distressed financials. The stock attracts biotech momentum traders betting on turnaround scenarios, acquisition speculation, or near-term catalysts. Not suitable for value or income investors given negative equity and no path to profitability visible in current financials.
high - Micro-cap biotech with existential liquidity risk, binary clinical/regulatory catalysts, and low float creates extreme volatility. Stock likely trades on low volume with wide bid-ask spreads and susceptibility to sharp moves on any news. Beta likely exceeds 2.0 given the risk profile and recent 72% three-month swing followed by sustained decline.